A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes
Phase 1
Completed
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Drug: GW786034 (pazopanib)Drug: Probe drugs
- Registration Number
- NCT00401583
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
This is a Phase I study to determine the effect of GW786034 (pazopanib) on P450 enzymes. This study will help determine which types of drugs may interact with GW786034.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Pazopanib receivers GW786034 (pazopanib) During Days 1 and 2 subjects will be dosed with only probe drugs, and with no drugs on Days 3-5. During Days 6 to the end of the study, subjects will receive 800 mg daily pazopanib, and on Days 23-24 subjects will receive probe drugs in addition to pazopanib Pazopanib receivers Probe drugs During Days 1 and 2 subjects will be dosed with only probe drugs, and with no drugs on Days 3-5. During Days 6 to the end of the study, subjects will receive 800 mg daily pazopanib, and on Days 23-24 subjects will receive probe drugs in addition to pazopanib
- Primary Outcome Measures
Name Time Method To investigate the potential of GW786034 to inhibit or induce various CYP450 enzymes. throughout the study
- Secondary Outcome Measures
Name Time Method Safety of co-administration of 800 mg daily GW786034 and CYP450 probe drugs. To describe GW786034 steady-state pharmacokinetics on this once daily dosing regimen. throughout the study
Trial Locations
- Locations (1)
GSK Investigational Site
🇸🇬Singapore, Singapore